Course: Relapsed/Refractory Multiple Myeloma: The Role of Community Hematologists/Oncologists in Advancing Care
CME Credits: 1.00
Released: 2026-07-31
Significant advancements in multiple myeloma treatment have occurred in recent years, resulting in improved survival and quality of life for many patients. However, the condition remains incurable, and treatment resistance and disease relapse persist despite multiple lines of therapy. In community oncology settings, significant disparities in access to advanced therapies and outcomes are common, resulting in lower clinical trial participation, long travel distances to specialty treatment centers, and limited access to oncology specialists. In this on-demand CME/CE activity, expert faculty will review recent clinical trial evidence and guideline recommendations for the treatment of relapsed/refractory multiple myeloma. The program will also highlight ways to improve adverse event monitoring, patient-clinician communication, and patient education in community-based settings. This enduring activity is a recorded session from Oncology Congress Spring 2026 that took place on June 13, 2026.
Upon completion of this activity, participants should be better able to:
View Full Course